Loading…
No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer
The renin-angiotensin system (RAS) was investigated as a target for cancer treatment. A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free surviv...
Saved in:
| Published in: | Anticancer research 2016-09, Vol.36 (9), p.4965-4970 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c344t-e5feb7a1b658d78537bf466edc7790c5c90f75a7171e1bbc919ecb5b82b8f3123 |
|---|---|
| cites | |
| container_end_page | 4970 |
| container_issue | 9 |
| container_start_page | 4965 |
| container_title | Anticancer research |
| container_volume | 36 |
| creator | Nakai, Yousuke Isayama, Hiroyuki Sasaki, Takashi Takahara, Naminatsu Saito, Kei Takeda, Tsuyoshi Umefune, Gyotane Saito, Tomotaka Takagi, Kaoru Watanabe, Takeo Hamada, Tsuyoshi Uchino, Rie Mizuno, Suguru Yamamoto, Keisuke Kogure, Hirofumi Matsubara, Saburo Yamamoto, Natsuyo Ijichi, Hideaki Tateishi, Keisuke Tada, Minoru Koike, Kazuhiko |
| description | The renin-angiotensin system (RAS) was investigated as a target for cancer treatment.
A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored.
The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified.
No survival benefit from ASIs was observed in BTC. |
| doi_str_mv | 10.21873/anticanres.11065 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1820596800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1820596800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-e5feb7a1b658d78537bf466edc7790c5c90f75a7171e1bbc919ecb5b82b8f3123</originalsourceid><addsrcrecordid>eNpFkE1PAjEYhBujEUR_gBfTo5fFdkvb3SMQP0iIJoInD5u2vJWa3S62XRL-vQT8OM0cZiaTB6FrSoY5LSS7Uz45o3yAOKSUCH6C-lSWNJOckVPUJzknmSSE99BFjJ-ECFEW7Bz1cikYYVz20ftzixdd2LqtqvEEPFiXsA1tg9Ma8MyvnXbJtR63Fr-Cdz4b-w_XJvDRebzYxQQN3ruJq50KO7wMyiQ8Vd5AuERnVtURrn50gN4e7pfTp2z-8jibjueZYaNRyoBb0FJRLXixkgVnUtuRELAyUpbEcFMSK7mSVFKgWpuSlmA010WuC8tozgbo9ri7Ce1XBzFVjYsG6lp5aLtY0SInvBQFIfsoPUZNaGMMYKtNcM3-eEVJdWBa_TOtDkz3nZuf-U43sPpr_EJk36OAdYo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1820596800</pqid></control><display><type>article</type><title>No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer</title><source>EZB Electronic Journals Library</source><creator>Nakai, Yousuke ; Isayama, Hiroyuki ; Sasaki, Takashi ; Takahara, Naminatsu ; Saito, Kei ; Takeda, Tsuyoshi ; Umefune, Gyotane ; Saito, Tomotaka ; Takagi, Kaoru ; Watanabe, Takeo ; Hamada, Tsuyoshi ; Uchino, Rie ; Mizuno, Suguru ; Yamamoto, Keisuke ; Kogure, Hirofumi ; Matsubara, Saburo ; Yamamoto, Natsuyo ; Ijichi, Hideaki ; Tateishi, Keisuke ; Tada, Minoru ; Koike, Kazuhiko</creator><creatorcontrib>Nakai, Yousuke ; Isayama, Hiroyuki ; Sasaki, Takashi ; Takahara, Naminatsu ; Saito, Kei ; Takeda, Tsuyoshi ; Umefune, Gyotane ; Saito, Tomotaka ; Takagi, Kaoru ; Watanabe, Takeo ; Hamada, Tsuyoshi ; Uchino, Rie ; Mizuno, Suguru ; Yamamoto, Keisuke ; Kogure, Hirofumi ; Matsubara, Saburo ; Yamamoto, Natsuyo ; Ijichi, Hideaki ; Tateishi, Keisuke ; Tada, Minoru ; Koike, Kazuhiko</creatorcontrib><description>The renin-angiotensin system (RAS) was investigated as a target for cancer treatment.
A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored.
The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified.
No survival benefit from ASIs was observed in BTC.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.11065</identifier><identifier>PMID: 27630357</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Biliary Tract Neoplasms - drug therapy ; Biliary Tract Neoplasms - pathology ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Renin-Angiotensin System - drug effects ; Treatment Outcome</subject><ispartof>Anticancer research, 2016-09, Vol.36 (9), p.4965-4970</ispartof><rights>Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-e5feb7a1b658d78537bf466edc7790c5c90f75a7171e1bbc919ecb5b82b8f3123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27630357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakai, Yousuke</creatorcontrib><creatorcontrib>Isayama, Hiroyuki</creatorcontrib><creatorcontrib>Sasaki, Takashi</creatorcontrib><creatorcontrib>Takahara, Naminatsu</creatorcontrib><creatorcontrib>Saito, Kei</creatorcontrib><creatorcontrib>Takeda, Tsuyoshi</creatorcontrib><creatorcontrib>Umefune, Gyotane</creatorcontrib><creatorcontrib>Saito, Tomotaka</creatorcontrib><creatorcontrib>Takagi, Kaoru</creatorcontrib><creatorcontrib>Watanabe, Takeo</creatorcontrib><creatorcontrib>Hamada, Tsuyoshi</creatorcontrib><creatorcontrib>Uchino, Rie</creatorcontrib><creatorcontrib>Mizuno, Suguru</creatorcontrib><creatorcontrib>Yamamoto, Keisuke</creatorcontrib><creatorcontrib>Kogure, Hirofumi</creatorcontrib><creatorcontrib>Matsubara, Saburo</creatorcontrib><creatorcontrib>Yamamoto, Natsuyo</creatorcontrib><creatorcontrib>Ijichi, Hideaki</creatorcontrib><creatorcontrib>Tateishi, Keisuke</creatorcontrib><creatorcontrib>Tada, Minoru</creatorcontrib><creatorcontrib>Koike, Kazuhiko</creatorcontrib><title>No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The renin-angiotensin system (RAS) was investigated as a target for cancer treatment.
A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored.
The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified.
No survival benefit from ASIs was observed in BTC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</subject><subject>Biliary Tract Neoplasms - drug therapy</subject><subject>Biliary Tract Neoplasms - pathology</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Renin-Angiotensin System - drug effects</subject><subject>Treatment Outcome</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpFkE1PAjEYhBujEUR_gBfTo5fFdkvb3SMQP0iIJoInD5u2vJWa3S62XRL-vQT8OM0cZiaTB6FrSoY5LSS7Uz45o3yAOKSUCH6C-lSWNJOckVPUJzknmSSE99BFjJ-ECFEW7Bz1cikYYVz20ftzixdd2LqtqvEEPFiXsA1tg9Ma8MyvnXbJtR63Fr-Cdz4b-w_XJvDRebzYxQQN3ruJq50KO7wMyiQ8Vd5AuERnVtURrn50gN4e7pfTp2z-8jibjueZYaNRyoBb0FJRLXixkgVnUtuRELAyUpbEcFMSK7mSVFKgWpuSlmA010WuC8tozgbo9ri7Ce1XBzFVjYsG6lp5aLtY0SInvBQFIfsoPUZNaGMMYKtNcM3-eEVJdWBa_TOtDkz3nZuf-U43sPpr_EJk36OAdYo</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Nakai, Yousuke</creator><creator>Isayama, Hiroyuki</creator><creator>Sasaki, Takashi</creator><creator>Takahara, Naminatsu</creator><creator>Saito, Kei</creator><creator>Takeda, Tsuyoshi</creator><creator>Umefune, Gyotane</creator><creator>Saito, Tomotaka</creator><creator>Takagi, Kaoru</creator><creator>Watanabe, Takeo</creator><creator>Hamada, Tsuyoshi</creator><creator>Uchino, Rie</creator><creator>Mizuno, Suguru</creator><creator>Yamamoto, Keisuke</creator><creator>Kogure, Hirofumi</creator><creator>Matsubara, Saburo</creator><creator>Yamamoto, Natsuyo</creator><creator>Ijichi, Hideaki</creator><creator>Tateishi, Keisuke</creator><creator>Tada, Minoru</creator><creator>Koike, Kazuhiko</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160901</creationdate><title>No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer</title><author>Nakai, Yousuke ; Isayama, Hiroyuki ; Sasaki, Takashi ; Takahara, Naminatsu ; Saito, Kei ; Takeda, Tsuyoshi ; Umefune, Gyotane ; Saito, Tomotaka ; Takagi, Kaoru ; Watanabe, Takeo ; Hamada, Tsuyoshi ; Uchino, Rie ; Mizuno, Suguru ; Yamamoto, Keisuke ; Kogure, Hirofumi ; Matsubara, Saburo ; Yamamoto, Natsuyo ; Ijichi, Hideaki ; Tateishi, Keisuke ; Tada, Minoru ; Koike, Kazuhiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-e5feb7a1b658d78537bf466edc7790c5c90f75a7171e1bbc919ecb5b82b8f3123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</topic><topic>Biliary Tract Neoplasms - drug therapy</topic><topic>Biliary Tract Neoplasms - pathology</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Renin-Angiotensin System - drug effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakai, Yousuke</creatorcontrib><creatorcontrib>Isayama, Hiroyuki</creatorcontrib><creatorcontrib>Sasaki, Takashi</creatorcontrib><creatorcontrib>Takahara, Naminatsu</creatorcontrib><creatorcontrib>Saito, Kei</creatorcontrib><creatorcontrib>Takeda, Tsuyoshi</creatorcontrib><creatorcontrib>Umefune, Gyotane</creatorcontrib><creatorcontrib>Saito, Tomotaka</creatorcontrib><creatorcontrib>Takagi, Kaoru</creatorcontrib><creatorcontrib>Watanabe, Takeo</creatorcontrib><creatorcontrib>Hamada, Tsuyoshi</creatorcontrib><creatorcontrib>Uchino, Rie</creatorcontrib><creatorcontrib>Mizuno, Suguru</creatorcontrib><creatorcontrib>Yamamoto, Keisuke</creatorcontrib><creatorcontrib>Kogure, Hirofumi</creatorcontrib><creatorcontrib>Matsubara, Saburo</creatorcontrib><creatorcontrib>Yamamoto, Natsuyo</creatorcontrib><creatorcontrib>Ijichi, Hideaki</creatorcontrib><creatorcontrib>Tateishi, Keisuke</creatorcontrib><creatorcontrib>Tada, Minoru</creatorcontrib><creatorcontrib>Koike, Kazuhiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakai, Yousuke</au><au>Isayama, Hiroyuki</au><au>Sasaki, Takashi</au><au>Takahara, Naminatsu</au><au>Saito, Kei</au><au>Takeda, Tsuyoshi</au><au>Umefune, Gyotane</au><au>Saito, Tomotaka</au><au>Takagi, Kaoru</au><au>Watanabe, Takeo</au><au>Hamada, Tsuyoshi</au><au>Uchino, Rie</au><au>Mizuno, Suguru</au><au>Yamamoto, Keisuke</au><au>Kogure, Hirofumi</au><au>Matsubara, Saburo</au><au>Yamamoto, Natsuyo</au><au>Ijichi, Hideaki</au><au>Tateishi, Keisuke</au><au>Tada, Minoru</au><au>Koike, Kazuhiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>36</volume><issue>9</issue><spage>4965</spage><epage>4970</epage><pages>4965-4970</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The renin-angiotensin system (RAS) was investigated as a target for cancer treatment.
A total of 287 patients with biliary tract cancer (BTC) receiving chemotherapy were retrospectively studied to evaluate the role of inhibition of RAS by angiotensin system inhibitors (ASIs). Progression-free survival (PFS) and overall survival (OS) were compared between 74 patients with hypertension, on ASIs (ASI group), 50 patients with hypertension not on ASIs (non-ASI with HT group) and 163 patients without hypertension (non-HT group). Interactions between the use of ASIs and various subgroups were explored.
The median PFS was 3.6, 3.9 and 4.6 months (p=0.495) and the median OS was 11.6, 10.9 and 13.1 months (p=0.668), respectively. The use of ASIs was not associated with OS (hazard ratio 1.00, p=0.975) and no subgroups with better survival were identified.
No survival benefit from ASIs was observed in BTC.</abstract><cop>Greece</cop><pmid>27630357</pmid><doi>10.21873/anticanres.11065</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2016-09, Vol.36 (9), p.4965-4970 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1820596800 |
| source | EZB Electronic Journals Library |
| subjects | Adult Aged Aged, 80 and over Angiotensin-Converting Enzyme Inhibitors - administration & dosage Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - pathology Disease-Free Survival Female Humans Kaplan-Meier Estimate Male Middle Aged Renin-Angiotensin System - drug effects Treatment Outcome |
| title | No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T11%3A30%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20Survival%20Benefit%20from%20the%20Inhibition%20of%20Renin-Angiotensin%20System%20in%20Biliary%20Tract%20Cancer&rft.jtitle=Anticancer%20research&rft.au=Nakai,%20Yousuke&rft.date=2016-09-01&rft.volume=36&rft.issue=9&rft.spage=4965&rft.epage=4970&rft.pages=4965-4970&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.11065&rft_dat=%3Cproquest_cross%3E1820596800%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c344t-e5feb7a1b658d78537bf466edc7790c5c90f75a7171e1bbc919ecb5b82b8f3123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1820596800&rft_id=info:pmid/27630357&rfr_iscdi=true |